Literature DB >> 21554496

Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis.

P J Chien1, J H Yeh, H C Chiu, Y M Hsueh, C T Chen, M C Chen, C M Shih.   

Abstract

BACKGROUND AND
PURPOSE: Myasthenia gravis (MG) is an autoimmune disorder that may involve natural killer (NK) cells. Although NK cells are part of the innate immune system, they also influence adaptive immune responses. Double-filtration plasmapheresis (DFP) is an effective therapy for MG crisis. Thus, we examined the effects of DFP on the cytotoxicity of NK cells.
METHODS: A total of 20 patients with MG and 16 healthy controls were recruited for the study. Ficoll-Paque-isolated peripheral blood mononuclear cells (PBMCs) and K562 cells were used as the effector and target cells, respectively. NK cell cytotoxicity was analyzed using flow cytometry immediately before and after DFP and upon course completion.
RESULTS: Double-filtration plasmapheresis treatment decreased significantly the NK cell cytotoxicity in patients with MG, especially in good responders, those who were positive for acetylcholine receptor (AChR) antibodies, and those receiving immunosuppressants.
CONCLUSIONS: The decrease in NK cell cytotoxicity after DFP and the decline of AChR antibody titer were observed in good responders indicating that this could benefit patients with MG.
© 2011 The Author(s). European Journal of Neurology © 2011 EFNS.

Entities:  

Mesh:

Year:  2011        PMID: 21554496     DOI: 10.1111/j.1468-1331.2011.03424.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  10 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma.

Authors:  Hui Liu; Jianyu Li; Fengmei Wang; Yingtang Gao; Ying Luo; Peng Wang; Chenglong Li; Zhengyan Zhu
Journal:  Tumour Biol       Date:  2014-11-24

3.  Effects of combined traditional Chinese medicine with immunosuppressive agents for patients with myasthenia gravis.

Authors:  Guoyan Qi; Shanshan Gu; Peng Liu; Hongxia Yang; Huimin Dong
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Clinical characteristics and therapeutic evaluation of childhood myasthenia gravis.

Authors:  Zhi-Xiao Yang; Kai-Li Xu; Hui Xiong
Journal:  Exp Ther Med       Date:  2015-02-03       Impact factor: 2.447

5.  Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker.

Authors:  Tanel Punga; Rozen Le Panse; Mats Andersson; Frédérique Truffault; Sonia Berrih-Aknin; Anna R Punga
Journal:  Ann Clin Transl Neurol       Date:  2013-12-30       Impact factor: 4.511

6.  Efficacy and safety of double-filtration plasmapheresis treatment of myasthenia gravis: A systematic review and meta-analysis.

Authors:  Chaoying Liu; Peng Liu; Mei Ma; Hongxia Yang; Guoyan Qi
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

7.  miR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus.

Authors:  Shaolan Zhou; Jing Zhang; Pengfei Luan; Zhanbing Ma; Jie Dang; Hong Zhu; Qian Ma; Yanfeng Wang; Zhenghao Huo
Journal:  J Immunol Res       Date:  2021-05-06       Impact factor: 4.818

8.  Serum proteomic, peptidomic and metabolomic profiles in myasthenia gravis patients during treatment with Qiangji Jianli Fang.

Authors:  Chunmei Wang; Yonghai Lu; Zhixi Chen; Xiaobin Liu; Huangquan Lin; Hui Zhao; Jinyan Chen; Yiuwa Kwan; Saiming Ngai
Journal:  Chin Med       Date:  2012-07-28       Impact factor: 5.455

9.  Clinical Study of Effects of Jian Ji Ning, a Chinese Herbal Medicine Compound Preparation, in Treating Patients with Myasthenia Gravis via the Regulation of Differential MicroRNAs Expression in Serum.

Authors:  Chao Jiang; Ping Liu; Jingsheng Zhang; Wenjing Bao; Shaobo Qiu; Yan Liang; Lin Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-05       Impact factor: 2.629

Review 10.  Update on ocular myasthenia gravis in Taiwan.

Authors:  Chao-Wen Lin; Ta-Ching Chen; Jieh-Ren Jou; Lin-Chung Woung
Journal:  Taiwan J Ophthalmol       Date:  2018 Apr-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.